Trump Pushes for Lower Obesity Drug Prices and Medicare Coverage — Major Health Policy Shift
Washington, D.C. | November 6, 2025 — In a move that could reshape the U.S. healthcare landscape, former President Donald Trump is reportedly negotiating deals with leading pharmaceutical companies to lower the prices of popular obesity drugs and to make them eligible for Medicare coverage. The initiative, still in development, could bring once-exclusive weight-loss treatments within reach for millions of Americans struggling with obesity and diabetes-related conditions.
Talks with Major Drugmakers: Novo Nordisk and Eli Lilly
According to multiple reports from The Wall Street Journal, Reuters, and STAT News, Trump’s team has been in active discussions with Novo Nordisk and Eli Lilly — the manufacturers of the best-known GLP-1 drugs such as Ozempic, Wegovy, Rybelsus, and Mounjaro. These medications have become highly sought-after for their ability to help people lose significant weight and improve metabolic health, but they remain prohibitively expensive for most Americans.
Trump is reportedly pushing for a fixed price of around $149 per month for certain formulations — a steep discount from current retail prices that can exceed $1,000 a month without insurance. Negotiations are said to involve commitments by the companies to make drugs more accessible while expanding government coverage through Medicare and potentially Medicaid.
Obesity Drugs: A Market on Fire
Over the past two years, GLP-1 drugs have reshaped both the healthcare and pharmaceutical industries. The medications, originally developed to treat type-2 diabetes, have become a cultural phenomenon as celebrities, executives, and influencers publicly share their dramatic weight-loss results. Sales of Ozempic and Wegovy have skyrocketed, turning Novo Nordisk into Europe’s most valuable company and boosting Eli Lilly’s market capitalization to record levels.
But despite the hype, most ordinary Americans cannot afford these drugs. Even with insurance, out-of-pocket costs are often hundreds of dollars per month. Medicare, which covers more than 65 million older and disabled Americans, currently does not pay for obesity medications under federal law — a rule that Trump now appears determined to challenge.
Trump’s Economic Pitch: “Health Care for Working Americans”
In public comments last week, Trump framed the move as part of a broader effort to reduce the cost of living and make healthcare affordable again. “We’re going to get drug prices down — way down — especially for medicines that people truly need,” he said during a rally in Florida. “If these drugs can help Americans live better, healthier lives, they should not be priced out of reach.”
While no official policy document has been released, the proposal fits Trump’s longstanding populist message on healthcare costs. During his presidency, he pushed for international price indexing and transparency in hospital billing — initiatives that pressured pharmaceutical companies to justify their pricing models. Analysts see this new obesity drug initiative as an extension of that strategy, potentially combining free-market negotiation with targeted government incentives.
Medicare Negotiations Under the Inflation Reduction Act
Separately, the Biden-era Inflation Reduction Act (IRA) gave Medicare the authority to negotiate drug prices for the first time in U.S. history. That process began earlier this year, with Novo Nordisk among the first companies to strike a preliminary pricing deal for its diabetes drugs. Trump’s plan could accelerate and expand that framework, particularly for obesity drugs that were not included in the initial round.
Health economists note that adding obesity drugs to Medicare coverage could have a massive fiscal impact — potentially saving billions in long-term healthcare costs by reducing obesity-related diseases such as heart failure, hypertension, and diabetes. But it could also cost Medicare tens of billions upfront if demand surges rapidly.
Industry Reaction: Caution and Opportunity
Both Novo Nordisk and Eli Lilly have responded cautiously to media reports. In statements to Reuters, the companies said they “welcome any discussion that expands patient access while maintaining sustainability and innovation.” Privately, however, executives have expressed concern that deep discounts could erode profit margins and slow investment in next-generation weight-loss therapies.
Still, Wall Street analysts see potential upside if the program succeeds in expanding the overall market. “Even at lower prices, the volume could explode,” said Daniel Morris, a pharmaceutical analyst at Evercore ISI. “If 10 or 20 million new patients become eligible through Medicare or employer insurance, the total sales could actually rise.”
Public Health Experts Urge Caution
Some public health experts caution that lowering prices alone will not solve America’s obesity crisis. They point to the need for comprehensive lifestyle support, nutrition education, and safe exercise infrastructure. “Medications can help, but obesity is a complex disease influenced by environment, behavior, and economics,” said Dr. Laura Peterson, an endocrinologist at Johns Hopkins University. “We have to treat it holistically.”
Nonetheless, she welcomed the potential policy shift, noting that “making effective treatments accessible is better than leaving millions without options.”
Political Implications: Health Care as 2026 Election Issue
Analysts believe the obesity drug push could become a central talking point heading into the 2026 midterm elections. With healthcare affordability still ranking among voters’ top concerns, Trump’s focus on drug prices may resonate widely, even with moderates and independents. Democrats, meanwhile, are likely to argue that the initiative builds upon the foundations laid by the Inflation Reduction Act.
“Trump is tapping into a real pocketbook issue,” said political strategist Karen Houghton. “If he can show results on lowering prices that Biden only promised, it will be a strong message in swing states.”
Global Ripple Effects
If the United States succeeds in cutting obesity drug prices, experts expect ripple effects worldwide. Many countries benchmark their own drug costs against U.S. prices, meaning a domestic price drop could eventually make GLP-1 medications more affordable globally. In developing countries like India and Bangladesh, where obesity and diabetes are rising rapidly, that could be a major public health boost.
However, such benefits would likely take time to materialize, given different regulatory environments and patent protections. Still, the mere possibility of cheaper, Medicare-approved GLP-1 drugs has already triggered optimism among patient groups and insurers abroad.
What Happens Next
The Trump team has not yet disclosed a specific timeline for the policy rollout, but industry observers expect formal proposals within the next several months. In the meantime, Medicare officials continue implementing the IRA’s first wave of negotiated price reductions, which could serve as a model for the obesity drug deal.
If approved, this initiative could mark one of the most significant healthcare changes in a generation — expanding access to breakthrough treatments while reshaping how America thinks about obesity, prevention, and public spending.
Reporting sources: The Wall Street Journal, Reuters, STAT News, Scripps News, and Fierce Pharma.
Comments
Post a Comment